New film‐coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower‐risk MDS: Results of the randomized, phase II ECLIPSE study

Once‐daily deferasirox dispersible tablets (DT) have a well‐defined safety and efficacy profile and, compared with parenteral deferoxamine, provide greater patient adherence, satisfaction, and quality of life. However, barriers still exist to optimal adherence, including gastrointestinal tolerabilit...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am J Hematol
Hlavní autoři: Taher, Ali T., Origa, Raffaella, Perrotta, Silverio, Kourakli, Alexandra, Ruffo, Giovan Battista, Kattamis, Antonis, Goh, Ai‐Sim, Cortoos, Annelore, Huang, Vicky, Weill, Marine, Merino Herranz, Raquel, Porter, John B.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6585741/
https://ncbi.nlm.nih.gov/pubmed/28142202
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24668
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky